Lippoldt Darin 4
4 · NEUROCRINE BIOSCIENCES INC · Filed Dec 10, 2025
Insider Transaction Report
Form 4
Lippoldt Darin
Chief Legal Officer
Transactions
- Exercise/Conversion
Common Stock
2025-12-08$43.24/sh+4,376$189,218→ 47,781 total - Sale
Common Stock
2025-12-08$159.65/sh−4,376$698,615→ 43,405 total - Exercise/Conversion
Non-Qualified Stock Option
2025-12-08−4,376→ 0 totalExercise: $43.24Exp: 2027-02-06→ Common Stock (4,376 underlying)
Footnotes (3)
- [F1]The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2025. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- [F2]Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $159.50 to $159.76. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F3]The option was granted February 6, 2017 and vested monthly over four years. These options were due to expire on February 6, 2027.